The recognition of AXL as a critical mediator of AML pathogenesis has spurred the development of AXL-targeted therapies aimed at disrupting AXL signaling and sensitizing leukemia cells to conventional chemotherapy. This evidence concerns the gene AXL and acute myeloid leukemia.